PsiOxus Therapeutics Initiates Phase II Clinical Study

PsiOxus Therapeutics, Ltd. (PsiOxus) announced initiation of a Phase II study of MT-102, a small molecule therapeutic for the treatment of cancer- and age-related wasting. MT-102 is being developed to reverse the effects of cachexia, a wasting disease that accompanies cancer, heart failure, COPD, renal failure, cirrhosis and rheumatoid arthritis, and that is associated with significant morbidity and mortality. MT-102 is also in development for sarcopenia, the age-related loss of muscle mass and strength that affects one in five people by age 60.

See the full article here

For information on PsiOxus, see the news story University of Birmingham vaccine technology is rising star in new biotech company |